Indian Hospital Chain To Enter Drug-Making Business By Buying Firm
This article was originally published in PharmAsia News
India's largest hospital chain plans to get into the pharmaceutical business through an acquisition and into clinical trials in collaboration with foreign companies. Apollo Hospitals sees an opportunity to get into the drugs end of the health care at a time of depressed prices brought on by a bad global economy. Apollo, through a wholly owned subsidiary, already is close to signing joint ventures with two U.S. companies for Phase I and II trials of cancer and heart drugs. The Apollo group also conducts Phase III trials for several companies. (Click here for more
You may also be interested in...
The China National Biotec Group has filed the first application in China for the broad use of a COVID-19 vaccine, days after the national regulatory agency released review guidelines for the conditional approval of such products.
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.